Could anti-sickness drug end the misery for IBS patients?

24th March 2019

Could a commonly-prescribed anti-sickness drug be the answer for the 1.3 million people in the UK who suffer the pain and misery of irritable bowel syndrome with diarrhoea (IBS-D)?

A nationwide clinical trial, TRITON, led by Professor Robin Spiller in Nottingham will assess the medication ondansetron, which is currently used by doctors to help cancer patients cope with the nausea and vomiting associated with chemotherapy, radiotherapy and surgery.

The research will aim to establish whether a much lower dose of the drug could also be a successful treatment for the abdominal pain and urgent bowel movements typically experienced by IBS patients. Read the full press release on the University of Nottingham’s website

The TRITON study has also been featured in the Mail on Sunday Karen Andrews, Patient Advisory Group (PAG) member, shared her story as one of the first patients to benefit from the study.

If you would like to know more about the TRITON study and see if you are eligible to take part, please contact Dr David Gunn: David.Gunn@nottingham.ac.uk 0115 970 9966